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Amyloid 32-microglobulin is modified with
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'Amyloid 32-microglobulin is modified with N.(carboxymethyl)lysine
in dialysis-related amyloidosis. Recent work from this laboratory revealed
that advanced glycation end product was localized to amyloid deposits in
patients with dialysis-related amyloidosis by immunohistochemistry using
a monoclonal antibody to advanced glycation end product. To elucidate
the epitope of the antibody, N'-p-tosyl-L-lysine-methyl ester was incu-
bated with glucose in vitro, and then a compound reactive to the antibody
was purified from the incubate by buthanol extraction, XAD-2 column
chromatography, and high-performance liquid chromatography while the
reactivity was examined by enzyme linked immunosorbent assay. The
purified compound was identified as N°-(carboxymethyl)-N°-p-tosyl-L-
lysine-methyl ester by using secondary ion mass spectrometry, and 1H- and
'3C-nuclear magnetic resonance spectroseopy. The epitope of the anti-
body was identified as -CH2-NH-CH2-COOH by enzyme-linked immu-
nosorbent assay of compounds with structures similar to N-(carboxy-
methyl)lysine. Immunochemical study using the antibody demonstrated
the presence of N-(carboxymethyl)lysine in the 7-microglobulin dimer
(molecular weight 23929) isolated from the synovium amyloid of a
hemodialysis patient with dialysis-related amyloidosis. In conclusion,
amyloid 2-microglobulin is modified with N°-(carboxymethyl)lysine in
dialysis-related amyloidosis.
Dialysis-related amyloidosis (DRA) is a serious complication in
patients maintained on long-term dialysis [11. Carpal tunnel
syndrome (CTS), cystic lesions of long bones, particularly in the
femoral and humeral heads, destructive spondyloarthropathy, and
diffuse arthritis and periarthritis of the scapulohumeral region are
seen with increasing frequency as a consequence of amyloid
deposition in these patients. The major component of amyloid has
been demonstrated to be /32-microglohulin (!32m) [2—5]. Serum
levels of 2m in dialysis patients are markedly increased as a result
of reduced glomerular filtration. However, there is no significant
correlation between the serum level of 132m and the occurrence of
DRA [6].
[32m isolated from the amyloid deposits in patients with DRA
has been demonstrated to be modified with advanced glycation
end products (AGEs) [7]. AGE-modified 132m has also been
detected in the urine and sera of these patients but not in that of
healthy subjects. AGE-f2m may he involved in the pathogenesis
of DRA by stimulating the chemotaxis of monocytes, the secretion
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of IL-1 and TNF-a from macrophages, and the subsequent
synthesis of collagenase in synovial cells [8]. We demonstrated
that AGE was localized to amyloid deposits in patients with DRA
by immunohistochemistry using a monoclonal anti-AGE antibody
[9]. To clarify the mechanism of AGE modification of f32m-
amyloid, we studied the effects of 3-deoxyglucosonc [3-deoxy-D-
erythro-hexos-2-ulose (3-DG)I, a potent protein-crosslinking in-
termediate of the Maillard reaction, on the AGE modification of
132m, and quantitated the serum levels of 3-DG in dialysis patients.
Then, we found that 3-DG accumulating in uremic serum may be
involved in the AGE modification of 132m-amyloid [10].
To determine the epitope of the anti-AGE antibody, we
incubated N°'-p-tosyl-L-lysine-methyl ester with glucose to form
the AGE-modified N'-p-tosyl-L-lysine-methyl ester, and then
purified a compound that reacted with the antibody. N-p-tosyl-
L-lysine-methyl ester was used instead of lysine, because the
N'-amino group of lysine in proteins does not usually react with
glucose to form Amadori products and AGEs, and the hydropho-
bicity of the products provides the better separation by reversed
phase HPLC. In this study we found the epitope of the anti-AGE
antibody was N°-(carboxymethyl)lysine, and demonstrated that
the amyloid /32m dimer extracted from the DRA tissues was
modified with N-(carboxymethyl)1ysine.
Methods
In vitro preparation of A GE-modified N°-p-tosyl-L-lysine-methyl
ester (Tos-Lys-Me)
AGE-modified Tos-Lys-Me was produced by incubating 0.36 M
Tos-Lys-Me (Sigma Chemical Company, St. Louis, MO, USA)
with 1.78 M glucose in 200 m phosphate buffer (120 ml), pH 7.4
at 37°C for three months.
Extraction and separation of a compound that reacts with anti-
A GE antibody (A G-10)
After adding distilled water (280 ml) to the AGE-modified
Tos-Lys-Me solution, the incubate products were extracted two
times with 1-buthanol (400 ml) by shaking for three minutes and
centrifugation at 700 g for five minutes. The collected buthanol
layer was evaporated by a rotary evaporator. The concentrated
extract (13.6 g) was applied to XAD-2 column (20 cm X 3.5 cm
I.D.). The extract was separated by eluting with water (1 liter),
30% methanol (1 liter), 50% methanol (1 liter), 80% methanol (1
liter) and 100% methanol (1 liter), and then evaporated to dryness
1303
1304 Niwa et al: Modification of amyloid f32m with carboxymethyl lysine
by a rotary evaporator, yielding fractions with weights (g) of 2.8,
1.0, 0.77, 1.22 and 1.50, respectively. Since the immunoreactivities
of the fractions by enzyme linked immunosorbent assay (ELISA)
were 0, 34, 143, 73 and 23 arbitrary units/mg, respectively, the 50%
methanol extract was then separated by high performance liquid
chromatography (HPLC).
HPLC
The chromatograph assembly (Japan Spectroscopic Co., Tokyo,
Japan) consisted of a Model 880-PU pump, a Model 880-50
degasser, a Model 875-UV variable wave length detector, a Model
820-FP fluorescence detector, a Model Chromatocorder 12, and a
reverse phase column (Develosil ODS-UG-5, 250 mm X 4.6 mm
I.D., Nomura Chemical Co., Aichi, Japan) with a guard column
(Develosil ODS-UG-5, 10 mm X 4.0 mm ID.).
A mobile phase consisting of solution (A) (distilled water/acetic
acid, 100:0.08, vol/vol) and solution (B) (acetonitrile/acetic acid,
100:0.08, vol/vol) was delivered at a flow rate of 1 mi/mm at
ambient temperature. The mobile phase was linearly programmed
from 10% of solution (B) to 25% of solution (B) in 150 minutes.
The eluate was monitored by detection of ultraviolet (254 nm) and
fluorescence (excitation: 370 nm and emission: 440 nm). The
concentrated extract eluted from XAD-2 column with 50% meth-
anol was injected into the HPLC. The eluates from the HPLC
were fractionated to about 60 tubes, and the collected fractions
were assayed for the reactivity to the anti-AGE antibody using
ELISA.
ELISA
The reactivity of each fraction to the anti-AGE antibody
(AG-b) was examined using a competitive ELISA. The sample
solution (25 .iJ) or standard AGE-HSA (0—1000 jxg/ml) was
incubated at room temperature for one hour in an AGE-HSA-
coated microplate with PBS (50 tl) containing 0.25% BSA and
peroxidase-conjugated anti-AGE antibody (AG-b). After wash-
ing four times with PBS, 0.087% o-phenylenediamine hydrochlo-
ride containing 0.02% H202 (100 xl) was added to the microplate.
The reaction was terminated with 0.8 M H2S04 (100 pA). The
absorption at 492 nm was measured using 620 nm as the control.
Secondary ion mass spectrometly (SIMS)
The molecular weight of peak 19 was determined by SIMS
using a double focusing mass spectrometer (M-2500, Hitachi Co.
Ltd, Japan). The compound was solubilized in methanol, and then
analyzed by using the mass spectrometer under the conditions of
the accelerating voltages of 9 kV for the first ion (Xe) and 4 kV
for the second ion, using glycerol as a matrix. The positive ion and
the negative ion mass spectra of peak 19 were obtained.
'H-NMR and '3C-NMR
The molecular structure of peak 19 was analyzed by using
1H-NMR and 13C-NMR. The 1H-NMR and '3C-NMR spectra
were obtained on JEOL JNM-A600 spectrometer operated at 600
MHz for proton and 150 MHz for carbon in the Fourier-
transform mode, respectively. Chemical shifts (b) were recorded
as parts per million (ppm) down-field from internal reference of
t-BuOH (1.28 ppm) in D20 and CD2HOD (3.325 ppm) in
CD3OD and coupling constants (J,) in hertz (Hz). The H-H and
C-H COSY spectra were obtained using a pulse sequence sup-
plied from JEOL.
Extraction of 132in dimer from amyloid tissue of a patient on HD
The 2m dimer fraction was extracted from DRA tissues as
described in detail in a previous paper [10]. Briefly, an amyloid
tissue was homogenized in 0.15 M NaCI and the homogenate was
centrifuged at 12,000 g for 30 minutes. The supernatant was
discarded, and the pellet was again homogenized and recentri-
fuged. This extraction procedure was repeated until absorption
(OD 280 nm) of the supernatant decreased less than 0.05. The
lyophilized amyloid fibrils were dissolved in 80% formic acid for
eight hours at room temperature, centrifuged at 12,000 g for 60
minutes, and separated according to molecular size on Sephadex
G-75 Superfine (Pharmacia) gel permeation chromatography at
4°C. The chromatogram monitored at UV 280 nm was composed
of three peaks. f32m levels in each fraction were quantified using
ELISA, demonstrating that the second and the third peaks
contained 2m. The second and the third peaks were found to be
132m dimer and /32m monomer, respectively, by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE).
SDS-PAGE and Western blotting
Electrophoresis was conducted by Tricine SDS-PAGE using
10% T and 3% C gels for the native 132m (Sigma) and /32m dimer
extracted from DRA tissue. The gel was produced by 6.1 ml of
acrylamide solution (3% C) (48 g acrylamide and 1.5 g BIS in 100
ml), 10 ml of 3 M Tris buffer (pH 8.45) containing 0.3% SDS, 4 g
of glycerol, distilled water (which was added until the total volume
of the solution became 30 ml), 150 xl of 10% ammonium
persulfate and 15 pA of TEMED. The electrolyte solution used for
the anode was 0.2 M Tris buffer (pH 8.9), and that for the cathode
was 0.1 M Tris buffer (pH 8.3), 0.1 M Tricine, and 0.1% SDS. After
applying the sample solution (5 jd) with 10 pA of 50 mvi Tris-HCI
buffer (pH 6.8) containing 12% glycerol, 4% SDS and 2%
2-mercaptoethanol to the gel, SDS-PAGE was performed at 40 V
overnight.
After SDS-PAGE, the proteins in the gel were transferred to
nitrocellulose membranes for Western blotting of J32m or PVDF
membranes for AGE at 10 V for 40 minutes (/32m) or one hour
(AGE) in a buffer containing 1000 ml of 50 mrvi Tris and 0.38 M
glycine, 100 ml methanol and 900 ml water. The membranes were
immersed at 4°C overnight in 10 ml of buffer A (10 mM Tris-HC1
buffer, pH 7.4, containing 0.8% NaCI, and 0.1% NaN3) containing
1% bovine serum albumin (BSA). Then, rabbit anti-human f32m
antibody solution (15 pA) (DAKOPATTS) or monoclonal anti-
AGE antibody solution (30 xl, AG-b), was added into the
solution, and reacted by shaking with the proteins at room
temperature for 90 minutes. After reaction, the membrane was
washed five times with 10 ml of buffer A, and soaked by shaking
in 10 ml of buffer A containing 1% BSA and 15 pA of peroxidase-
labeled anti-rabbit IgG or 30 id of peroxidase-labeled anti-mouse
IgG (Miles Scientific). After washing five times with 10 ml of
buffer A, the membranes were stained with 10 ml of a water
solution containing 0.7 mg 3,3'-diaminohenzidine and 10 pA of
H202.
Electrospray ionization liquid chromatography-mass spectrometiy
(ESI-LC/MS)
To determine the molecular weight of the f32m dimer extracted
from DRA tissue, the j32m dimer was analyzed by ESI-LC/MS.
The ESI mass spectra were obtained on a mass spectrometer
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(TSQ 7000, Finnigan MAT Instruments, Inc., San Jose, CA, USA)
equipped with a PLRP-S 1000A column (50 mm X 1.0 mm I.D.,
8 xm). A mobile phase consisting of solution (A) (distilled
water/acetic acid, 100:2, vol/vol) and solution (B) (acetonitrile/
acetic acid, 100:2, vol/vol) was delivered at a flow rate of 50 jxl/min
at ambient temperature. The mobile phase was linearly pro-
grammed from 10% of solution (B) to 60% of solution (B) in 50
minutes. The eluate was injected to the mass spectrometer
through a UV monitor (290 nm). The amyloid 132m dimer was
detected by UV and ESI-MS with a retention time of 20 minutes.
The conditions for ESI were: electric field, 4.5 kV; nitrogen sheath
gas, 60 psi; auxiliary gas, 5 units; and capillary temperature, 175°C.
Matri.x-assisted laser desorption ionization-time of flight mass
spectrometty (MALDI- TOFMS)
The molecular weight of native /32m and amyloid 132m monomer
was determined by MALDI-TOFMS using Vision 2000 (Finnigan
MAT) and 2,5-dihydroxybenzoic acid as a matrix.
Results
Figure 1 shows the HPLC chromatograms of the 50% methanol
extract from XAD-2 column separation of the AGE-modified
Tos-Lys-Me solution. The fraction which contained the whole
peak 19 was found to be reactive with the anti-AGE antibody
(AG-b), but the fractions adjacent to peak 19 did not show any
reactivity with the anti-AGE antibody. Thus, peak 19 without
fluorescence exactly corresponds to the ELISA detectable peak.
Peak 19 fractions were collected and evaporated to a residue (3.0
mg) by a rotary evaporator.
Figure 2 shows the positive ion and negative ion mass spectra of
peak 19, demonstrating that its molecular weight is 372. Since the
molecular weight of Tos-Lys-Me was 314, the increase in the
molecular weight of peak 19 from Tos-Lys-Me was 58, was found
to be due to the conversion from -NH2 to -Nl-l-CH2-COOH as
demonstrated by NMR data. Table 1 shows the H-NMR and
'3C-NMR data of peak 19 and their assignments. Figure 3 shows
the chemical structure of N-(carhoxymethyl)-Tos-Lys-Me. The
NMR data of peak 19 demonstrate the similar spectra to those of
Tos-Lys-Me, except for the presence of additional peaks of C-i',
185 (2G+H) 373 (M+Hy
745 (2M+H)
1 Ii . I ..
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Fig. 2. Positive ion (A) and negative ion (B) mass spectra of peak 19. The
molecular weight of peak 19 was found to be 372, indicating the increase
in mass by 58 as compared to Tos-Lys-Me (molecular weight, 314).
C-2' and H-2' which derive from an additional carboxymethyl
group (-CFI2-COOH). The molecular weight information and the
NMR data clearly demonstrate the chemical structure of N-
(carboxymethyl)-Tos-Lys-Me.
Figure 4 shows the reactivity of the antibody to peak 19
[N-(carhoxymethy1)-Tos-Lys-Me and the compounds with car-
boxymethyl groups. The antibody reacted strongly with peak 19
[N-(carboxymethyl)-Tos-Lys-Mcj among the compounds tested,
11)(IC0a-(I)
a)I
0 10 20 30 40 50 60 70 80 90100110120130140
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Fig. 1. HPLC chromatograms with UV and
fluorescence Fl) detection of the 50% methanol
eluate from XAD-2 column separation of the
A GE-modified Tos-Lys-Me solution. The
fractions were assayed for the reactivity to the
anti-AGE antibody (AG-b) by ELISA. Peak 19
fraction, which eluted at about 40 minutes
without fluorescence, was found to be reactive
with the anti-AGE antibody.
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C No. b C ppm H No. b H ppm
c-i 172.7
C-2 56.1 H-2 3.98 (IH, dd, J = 5.5 and 9.2 Hz)
C-3 31.9 H-3a, b 1.6 - 1.8 (2H, m)
C-4 23.3 H-4a, h 1.3 -- 1.4 (2H, m)
C-5 26.2 H-5 1.68 (2H, m)
C-6 47.3 H-6 3.02 (2H, t, J = 7.7 Hz)
C-7 51.5 H-7 3.48 (3H, s)
C-I' 175.3
C-2' 48.7 H-2' 3.61 (2H, s)
C-i" 146.9
C-2", 6" i28.5 (2C) H-2", 6" 7.77 (2H, d, J 8.0 Hz)
C-3", 5" 131.8 (2C) H-3", 5" 7.49 (2H, d, J = 8.0 Hz)
C-4" 136.8
C-7" 22.2 H-7" 2.47 (3H, s)
Fig. 3. Chemical structure of N-(carbox-ymethyl)-Tos-Lys-Me.
and did not react with Tos-Lys-Me itself. The other compounds
that did not react with the antibody, had only NH(2)-CH2-COOH,
CH-NH-CH2-COOH, or C-NH-CH2-COOH, demonstrating that
the epitope of the antibody was -CH2-NH-CH2-COOH.
Modification of amyloid 132m dimer with N-(carboxymethy1)lysine
Figure 5 shows the photographs of Western blotting using
anti-human 2m antibody and anti-AGE antibody (AG-b) after
separation by SDS-PAGE of the amyloid 2m dimer. The amyloid
132m dimer was demonstrated to be modified with N-(carboxy-
methyl)lysine by positive immunostaining with the anti-AGE
antibody, the epitope of which was found to be the carboxym ethyl
group in N-(carboxymethyl)lysine. This finding was also con-
firmed by the evidence that the preincubation of anti-AGE
antibody with N-(carboxymethy1)-Tos-Lys-Me resulted in nega-
tive staining on the Western blot for amyloid f32m dimer. Figure 6
shows the ES! mass spectra of the amyloid f32m dimer, demon-
strating that its molecular weight is approximately 23929.
Amyloid 132m monomer showed almost the same average
molecular weight as native 2m [m/z 11727.9, (M + H), vs. m/z
11726.6, (M + H)] (Fig. 7). However, amyloid 2m showed a
mM
Fig. 4. Competitive ELISA determining the reactivity of anti-AGE body
(AG-JO) to peak 19 [N-(carboxymethyl)-Tos-Lys-Me] and compounds with
structures similar to peak 19. The antibody reacted with W-(carboxymeth-
yl)-Tos-Lys-Me, but not with Tos-Lys-Me. Thus, the epitope of the
antibody was found to be -CH2NHCH2COOH, because the antibody did
not react with the compounds with the structure of NH(2)CH2COOH,
CHNHCH2COOH or CNHCH2COOH. Symbols are: (•) Peak 19 (Ne-
carboxymethyl-N-p-tosyl-L-lysine methyl ester); (A) N-p-tosyl-L-lysine
methyl ester; (V) Glycine; (X) N-carboxymethyl-nicotinamide adenine
dinucleotide; (LI) N-Methylglycine; (0) N-carboxymethyl-adenosine 5'-
monophosphate; (A) N-carboxymethyl-L-phenylalanyl-L-leucine.
much broader peak compared to native 132m, suggesting the
heterogeneity of amyloid j32m monomer.
Discussion
Our results demonstrate that amyloid 2m dimer extracted
from DRA tissue is modified with N-(carboxymethyl)lysine, and
has the mean molecular weight of approximately 23929 (the
molecular weight of native 132m is 11729). The molecular weight of
the amyloid f32m dimer suggests that it is modified not only with
N-(carboxymethyl)lysine residues but also with the other
crosslinking AGE structures.
Glucose reacts nonenzymatically with protein amino groups to
initiate glycation, the early stage of the Maillard reaction. This
process begins with the conversion of reversible Schiff base
adducts to stable, covalently bound Amadori rearrangement
products. The levels of the Amadori products on numerous
proteins are elevated in proportion to the degree of hyperglyce-
mia in diabetes mellitus. In the intermediate stage of the Maillard
reaction, the Amadori products can undergo multiple dehydration
and rearrangements to produce highly reactive carbonyl com-
pounds such as 3-DG [11—14], which reacts again with free amino
groups, leading to crosslinking and browning of the proteins via
the formation of AGEs in the late stage of the Maillard reaction.
We found that the serum levels of 3-DG were markedly increased
in not only diabetic patients [151 but also dialysis patients [10,16].
Aniadori products can also undergo partial degradation, form-
ing N-(carboxymethyl)lysine. W-(carboxymethyl)lysine was orig-
inally detected in vitro as a product of oxidative cleavage of
glucose-derived Amadori compounds [17]. However, N-(car-
boxymethyl)Iysine has also been detected in vivo in lens protein
[18] and skin collagen [19] as the result of aging of the proteins,
and its levels were increased in diabetic patients, consistent with
the hypothetical role of the Maillard reaction in the accelerated
aging of proteins in diabetes mellitus. N-(carboxymethyl)lysine
Table 1. H-NMR and 3C-NMR data of peak 19 in Figure 1
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Fig. 5. Western blotting using anti-human /32m antibody and anti-AGE antibody (AG-b) after separation by SDS-PAGE of amyloid 132m dimer extracted
from DRA tissue. The amyloid J32m dimer was demonstrated to be modified with N—(carboxymethyl)lysine. Lanes I are f32m; Lanes 2 are /32m dimer.
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may also be derived from reactions of proteins with ribose,
threose, and other sugars [20]. We also found that the reaction of
2m with 3-DG produced N-(carboxymethyI)lysine, because the
incubate of f32m with 3-DG produced /32m and its dimer that react
with the anti-AGE antibody [10], the epitope of which was found
to be N-(carboxymethyl)lysine. Since the serum levels of 3-DG
were markedly increased in dialysis patients [10,16], the modifi-
cation of amyloid 2m with W-(carboxymethyl)lysine may pro-
ceed by the reaction of j32m with 3-DG after deposition of f32m in
the amyloid tissues even under normoglycemia.
The term of AGE is now applied to a wide range of advanced
products of the Maillard reaction, including N-(carboxymethyl)
lysine and pyrraline, compounds which do not have color or
fluorescence, and do not crosslink proteins. However, like pento-
sidine, N-(carboxymethyl)lysine accumulates with age in colla-
gen, and is considered to be a useful biomarker for the Maillard
reaction damage to tissue proteins. Since N-(carboxymethyl)
lysine is probably located on the surface of most AGE-modified
proteins due to its polarity, it is an exposed and easily recognizable
antigenic determinant, and thus is a major AGE recognized in
tissue proteins by polyclonal antibodies to AGE-modified proteins
[211. AGEs have been reported to be biologically active on
macrophages [22,23]. However, it has not yet been reported that
N-(carboxymethyl)lysine is biologically active on macrophages.
The chemical modification of long-lived proteins, such as lens
crystalline and collagen via the Maillard reaction, has been
postulated to contribute to the development of pathologies asso-
ciated with aging and diabetes mellitus, such as cataract, nephrop-
athy, neuropathy and vascular diseases [24—26]. The in vivo
presence of AGE has been demonstrated in human lens crystal-
line [27], human hemoglobin [28], f32m [7], /3-amyloid peptide and
tau protein [29—31]. Several compounds such as pyrraline [32],
pentosidine [33], crosslines [34] and imidazolones [35,36] have
been proposed as the structures of AGE. These AGE structures
may also be involved in the /32m dimer extracted from DRA
tissues, because reactions of proteins with 3-DG are known to
produce pyrraline, pentosidine, and imidazolones.
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Fig. 6. (A). ESI mass spectra of the amyloid (32m dimer, demonstrating that its
molecular weight was approximately 23929. (B). Deconvolution spectrum.
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In conclusion, the epitope of the anti-AGE antibody we pro-
duced is N-(carboxymethy1)lysine, and the amyloid /32m dimer
extracted from DRA tissue is modified with N-(carboxymethyl)
lysine.
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